Amgen
Developing innovative human therapeutics
- B2B
- B2C
- Has physical offices
- Publicly traded
- Manufacturing
- Multi-product
- Sales-led purchase
About Amgen
This biotechnology company focuses on discovering and developing innovative therapeutics to improve health outcomes for patients with serious illnesses worldwide
Key facts
- Industry
- Biotechnology Research
- Company size
- 10,000+ employees
- Headquarters
- Thousand Oaks, California, United States
- Founded
- 1980
- Revenue
- $36.8BFY2025, publicly reported
- Website
- amgen.com
- linkedin.com/company/amgen
Jobs at Amgen
- Associate Director, Data Strategy and Governance
- Senior Director, Global GMP/GDP Audit and Predictive Compliance Intelligence
- Senior Manager – Manufacturing Programs - Process Owner Organization
- Business Performance & Analytics Analyst
- Product Owner - Data Assets Platform
- Manager Manufacturing Programs – Process Owner Team
- Finance Manager - Product Analytics and Insights (x2)
- Corporate Facilities & Engineering Senior Manager (Remote Global Reliability Network Lead)
Amgen in the news
- Amgen (NASDAQ:AMGN) Scores Late-Stage Immunology Win
Amgen achieved a late-stage immunology win with positive data for an autoimmune condition candidate, while also focusing on a lead obesity candidate and benefiting from a broader market rotation towards healthcare.
- More Than Skin Deep: Understanding Discoid Lupus Erythematosus
Amgen is dedicated to advancing the understanding and treatment of discoid lupus erythematosus (DLE), an autoimmune skin condition with limited current therapeutic options.
- Amgen (AMGN) Stock Dips While Market Gains: Key Facts
Amgen's stock dipped 3.38% to $407.27, underperforming market gains, with upcoming earnings projected to show growth.
- Amgen Inc Stock (AMGN) Closed Down by 3.38% on Oct 1: What Investors Need To Know
Amgen Inc. stock fell 3.38% on October 1st due to profit-taking, valuation recalibration, and concerns over pipeline timelines, competitive pressures, and substantial debt.
- Amgen Readies Daxdilimab For Phase III In Discoid Lupus After Mid-Stage Trial
Amgen is advancing Daxdilimab into Phase III trials for discoid lupus following positive mid-stage results.
Amgen at a glance
Amgen is a B2B/B2C company in the Biotechnology Research industry, headquartered in Thousand Oaks, California, United States.
Amgen was founded in 1980.
Amgen has 10,000+ employees.
Amgen's revenue is $36.8B (FY2025, publicly reported).
Amgen is hiring: 8 recent open roles, including Associate Director, Data Strategy and Governance, Senior Director, Global GMP/GDP Audit and Predictive Compliance Intelligence, Senior Manager – Manufacturing Programs - Process Owner Organization.
Selling to companies like Amgen?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies